newsfilter
← Latest News
ACCESS Newswire·

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

- DMT310 Phase 3 Spongilla Treatment of Acne Research clinical trial has enrolled over 50% of patients- Dermata continues discussions with potential botulinum toxin partners for DMT410- Raised $2.3 million in